The efficacy and safety for T2DM patients with OAD losing efficacy receiving insulin aspart 30 plus metformin compared with insulin aspart 30 monotherapy

Trial Profile

The efficacy and safety for T2DM patients with OAD losing efficacy receiving insulin aspart 30 plus metformin compared with insulin aspart 30 monotherapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2016

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top